Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H24N6O4 |
| Molecular Weight | 376.4103 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3NC4CCCC4
InChI
InChIKey=GWVQGVCXFNYGFP-PFHKOEEOSA-N
InChI=1S/C17H24N6O4/c1-2-18-16(26)13-11(24)12(25)17(27-13)23-8-21-10-14(19-7-20-15(10)23)22-9-5-3-4-6-9/h7-9,11-13,17,24-25H,2-6H2,1H3,(H,18,26)(H,19,20,22)/t11-,12+,13-,17+/m0/s1
| Molecular Formula | C17H24N6O4 |
| Molecular Weight | 376.4103 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Selodenoson (formerly DTI-0009) was developed by Aderis Pharmaceutical as a selective adenosine A1 full agonist to control heart rate in patients with atrial fibrillation while minimizing changes in blood pressure or decreases in heart function. The drug was studied in phase II clinical trial to treat the patients with supraventricular arrhythmias, however, this study was discontinued.
Approval Year
Sample Use Guides
In the trial, patients were randomized to receive placebo or selodenoson at 2, 4, 6, 8, 10 or 12 mcg/kg doses as a 15-minute infusion. The heart rate was reduced by all doses at 5, 15 (end of infusion) and 30 minutes after beginning the infusion.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:24:43 GMT 2025
by
admin
on
Mon Mar 31 18:24:43 GMT 2025
|
| Record UNII |
103G5E953K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C522396
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
3082555
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
C75135
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
300000034406
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
110299-05-3
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107371
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
103G5E953K
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
PP-01
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
8466
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY | |||
|
DTXSID00149201
Created by
admin on Mon Mar 31 18:24:43 GMT 2025 , Edited by admin on Mon Mar 31 18:24:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
